Loading patent…
AssigneeOXiGENE, Inc.
InventorsRonald W. Pero, Anders Olsson, Tomas Ekberg, Alan Schwartz, David Chaplin
Estimating the term…
Methods of killing tumor or cancer cells in human patients using an aryl N-substituted carboxamide having one or more aryl halo or one or more aromatic nitrogens, and/or acid addition salts thereof. The carboxamide may be an N-substituted nicotinamide or an N-substituted benzamide having such features, and may be used directly as a chemotherapeutic agent, or as a sensitizer for radiation or other chemotherapeutic agents. New compositions for such use include N-(2-diethylamino-ethyl)-4-amino-3-chlorobenzamide, N-(2-diethylamino-ethyl) nicotinamide, and their acid addition salts, e.g. hydrochlorides.
A method of inhibiting or killing tumor or cancer cells in a human patient, consisting essentially of treating the patient with a composition selected from the group consisting of N-(2-diethylamino-ethyl)-4-amino-3-chlorobenzamide, acid addition salts thereof, and mixtures thereof.
A method of inhibiting or killing tumor or cancer cells in a human patient, consisting essentially of treating the patient with radiation or a chemotherapeutic agent having a cytotoxic effect on said cells together with a composition selected from the group consisting of N-(2-diethylamino-ethyl)-4-amino-3-chlorobenzamide, acid addition salts thereof, and mixtures thereof, in an amount effective to enhance the cytotoxic effect of the radiation or chemotherapeutic agent employed.
A method of inhibiting or killing tumor or cancer cells in a human patient which comprises treating the patient with a composition comprising at least one compound selected from the group consisting of N-(2-diethylamino-ethyl)-4-amino-3-chlorobenzamide and acid addition salts thereof.
Dependencies are inferred from the claim text.